Opus Genetics shares rise 14.34% intraday after announcing participation in February 2026 medical and industry conferences.

think> Okay, let's start by analyzing the user's query. They want me to act as a financial analyst explaining the stock price movement of Opus Genetics (IRD) based on recent news. The stock had an intraday up of 14.34%, and there are several news events listed. First, I need to confirm the stock's movement and the trading period. The stock went up 14.34% intraday. The trading period is specified as intraday, so the movement happened during regular trading hours. Next, I have to evaluate each news event for relevance. The user provided multiple news items from GlobeNewswire, TipRanks, Barchart, etc. Let's go through them one by one. 1. Opus Genetics to participate in medical conferences in Feb 2026 – This is a future event, but participation in conferences can generate positive sentiment. However, it's scheduled for February 2026, which is a few months away. The stock's movement is recent, so the timing might not align unless the news was just released. The article is from 4 days ago. 2. Launched a gene therapy trial for MERTK-related RP – This is a significant positive event. Launching a clinical trial is a key milestone for biotech companies, often leading to stock price increases. The article is from 10 days ago. 3. Senti Bio's panel presentation at J.P. Morgan – Senti Bio is a different company, but the news mentions IRD (Opus) with a +17.39% tag. However, the main event is about Senti Bio, so this might be less relevant. The article is 28 days old. 4. Opus highlights 2025 progress and 2026 catalysts – This is a corporate update, which could be positive. The article is from 28 days ago. 5. Riskiest stocks with over 300% upside – This is an article about speculative stocks, which might affect investor sentiment. However, it's from 1 month ago and might not directly relate to the recent intraday jump. 6. Inducement grant announcement – This is about a Nasdaq rule compliance, which is administrative and less likely to impact stock price significantly. The article is 1 month old. 7. Presenting at J.P. Morgan 2026 Healthcare Conference – Similar to the first point, future event, but the article is from 1 month ago. 8. Positive DMC recommendation for Best Disease trial – This is a positive development for clinical trials, indicating the trial is on track. The article is 2 months old. 9. Piper Sandler initiates coverage with Overweight and $7 PT – Analyst coverage with a positive rating is bullish. The article is from 2 months ago. 10. Participating in investment conferences – Again, future event, but the article is 2 months old. 11. Dosing of first participant in Best Disease trial – Another positive milestone. The article is 2 months old. 12. Q3 loss but revenue beat – Mixed news, but revenue beating estimates could be positive. The article is 2 months old. 13. FDA meeting supporting advancement of OPGx-LCA5 – Positive regulatory news. The article is 2 months old. 14. $23M registered direct offering – This is a capital raise, which could be seen as a positive if it funds development but might be dilutive. The article is 2 months old. Now, the stock's intraday jump is 14.34%, which is a significant move. The most recent relevant news is the participation in the February 2026 conferences (4 days ago) and the gene therapy trial launch (10 days ago). However, these are both positive but older. The Piper Sandler coverage is 2 months old, and the positive DMC recommendation is also 2 months old. The stock's movement is intraday, so it's during regular trading. The key is to find the most recent and impactful news that could have caused the jump. But looking at the dates, the most recent news is from 4 days ago (conferences in Feb 2026) and 10 days ago (gene therapy trial). However, the stock's movement is a single intraday jump, not over a period. The question is whether any of the news events around the time of the jump could have caused it. However, the news provided doesn't have exact dates. The user provided "4d ago" for the first news and "10d ago" for the trial. If the stock's movement is today, then the news from 4 days ago might be too old. However, the user's instruction says "recent news events," so maybe all the listed news are considered recent. The challenge is that the stock's movement is a single intr.